celecoxib has been researched along with Colitis Gravis in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a placebo-controlled pilot trial to evaluate the safety of celecoxib in patients with ulcerative colitis in remission who had a present or past history of nonspecific arthritis, arthralgia, or other condition amenable to nonsteroidal anti-inflammatory drug therapy." | 5.12 | Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. ( Bloom, BJ; Brynskov, J; Kent, JD; Lorenz, RG; Robbins, JL; Sandborn, WJ; Steidle, GM; Stenson, WF, 2006) |
| "Several studies have shown the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) on 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis, but how these drugs act in case of inflammation-augmented tumorigenesis is still not clear." | 3.80 | Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis. ( Nehru, B; Sanyal, SN; Setia, S, 2014) |
| "A case history is described of a 38-year-old women, without digestive past, who presented with hemorrhagic ulcerated acute colitis beginning 2 days after starting celecoxib (200 mg/d) prescribed for sciatica." | 3.73 | [Ulcerating haemorrhagic colitis induced by celecoxib]. ( Andriamanantena, D; Carrère, C; Casassus-Builhè, D; Hamant, N; Perret, JL; Rey, P, 2005) |
| "Patients with Crohn's disease, ulcerative colitis, or pouchitis who used celecoxib or rofecoxib were identified from computerized prescription records." | 3.71 | Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. ( Loftus, EV; Mahadevan, U; Sandborn, WJ; Tremaine, WJ, 2002) |
| " While these drugs effectively reduce musculoskeletal pain and stiffness, long-term use is limited by gastrointestinal (GI) adverse effects (AEs) and disease exacerbation." | 2.50 | Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. ( Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y, 2014) |
| "Treatment with celecoxib-loaded NLCs alleviated severity of colitis as demonstrated by disease activity index, colon length, fecal occult blood test, and histopathological analysis." | 1.56 | Lipid-based nanocarrier-mediated targeted delivery of celecoxib attenuate severity of ulcerative colitis. ( Ahmad, A; Khan, R; Kumar, A; Mishra, RK; Raza, SS; Vyawahare, A, 2020) |
| "Development of ulcerative colitis was accompanied by the activation of iNOS/COX-2/5-LOX and increased contents of nitric oxide (NO), prostaglandin E₂ (PGE₂), and leukotriene B₄ (LTB₄)." | 1.37 | Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis. ( Fomenko, IS; Panasyuk, NB; Sklyarov, AY, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Malik, A | 1 |
| Stringer, E | 1 |
| Warner, N | 1 |
| van Limbergen, J | 1 |
| Vandersteen, A | 1 |
| Muise, A | 1 |
| Derfalvi, B | 1 |
| Kaur, R | 1 |
| Desai, D | 1 |
| Amin, S | 1 |
| Raza, K | 1 |
| Bhalla, A | 1 |
| Yadav, P | 1 |
| Kaushal, N | 1 |
| Mishra, RK | 1 |
| Ahmad, A | 1 |
| Kumar, A | 1 |
| Vyawahare, A | 1 |
| Raza, SS | 1 |
| Khan, R | 1 |
| Sheta, NM | 1 |
| Boshra, SA | 1 |
| Setia, S | 2 |
| Nehru, B | 2 |
| Sanyal, SN | 2 |
| Gugulothu, D | 1 |
| Kulkarni, A | 1 |
| Patravale, V | 1 |
| Dandekar, P | 1 |
| Miao, XP | 1 |
| Li, JS | 1 |
| Ouyang, Q | 1 |
| Hu, RW | 1 |
| Zhang, Y | 1 |
| Li, HY | 1 |
| Sklyarov, AY | 1 |
| Panasyuk, NB | 1 |
| Fomenko, IS | 1 |
| Rey, P | 1 |
| Andriamanantena, D | 1 |
| Carrère, C | 1 |
| Casassus-Builhè, D | 1 |
| Hamant, N | 1 |
| Perret, JL | 1 |
| Sandborn, WJ | 2 |
| Stenson, WF | 1 |
| Brynskov, J | 1 |
| Lorenz, RG | 1 |
| Steidle, GM | 1 |
| Robbins, JL | 1 |
| Kent, JD | 1 |
| Bloom, BJ | 1 |
| Bloomfeld, RS | 1 |
| Okayama, M | 1 |
| Hayashi, S | 1 |
| Aoi, Y | 1 |
| Nishio, H | 1 |
| Kato, S | 1 |
| Takeuchi, K | 1 |
| Mahadevan, U | 1 |
| Loftus, EV | 1 |
| Tremaine, WJ | 1 |
1 review available for celecoxib and Colitis Gravis
| Article | Year |
|---|---|
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygena | 2014 |
2 trials available for celecoxib and Colitis Gravis
| Article | Year |
|---|---|
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Colitis, Ulc | 2006 |
Are COX-2 inhibitors safe for anyone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Cyclooxygenase 2 Inhibitors | 2006 |
11 other studies available for celecoxib and Colitis Gravis
| Article | Year |
|---|---|
Multisystem Autoimmune Inflammatory Disease, Including Colitis, Due to Inborn Error of Immunity.
Topics: Adolescent; Agammaglobulinemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Autoim | 2021 |
Selenocoxib-3, a novel anti-inflammatory therapeutic effectively resolves colitis.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis; Coli | 2023 |
Lipid-based nanocarrier-mediated targeted delivery of celecoxib attenuate severity of ulcerative colitis.
Topics: Animals; Celecoxib; Colitis, Ulcerative; Drug Carriers; Lipids; Mice; Nanostructures; Particle Size | 2020 |
Fabrication and Evaluation of Celecoxib Oral Oleogel to Reduce the Inflammation of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Colon; Dextran Sul | 2021 |
Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Celecoxib; Colitis, Ulcerative; Colonic Neoplasms; Cyclooxygenase 2 | 2014 |
pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Celecoxib; Co | 2014 |
Celecoxib prevents colitis associated colon carcinogenesis: an upregulation of apoptosis.
Topics: Apoptosis; Celecoxib; Cell Cycle Checkpoints; Cell Proliferation; Colitis, Ulcerative; Colon; Coloni | 2014 |
Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis.
Topics: Acetic Acid; Animals; Antioxidants; Arachidonate 5-Lipoxygenase; Arginine; Benzoquinones; Celecoxib; | 2011 |
[Ulcerating haemorrhagic colitis induced by celecoxib].
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Femal | 2005 |
Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.
Topics: Animals; Cardiovascular Diseases; Celecoxib; Colitis, Ulcerative; Colon; Cyclooxygenase 1; Cyclooxyg | 2007 |
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
Topics: Adult; Aged; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2002 |